Zota Healthcare's Q2 FY27 showed sequential recovery at the operating level, but profitability remained weak. Consolidated revenue grew 54.6% YoY to Rs 200 crore, led by Davaindia (up 76.2% YoY to Rs 170 crore) on higher footfall and a better wallet spend. EBITDA turned positive Rs 3.1 crore on account of lower marketing expenses pertaining to brand ambassador spends but curtailed by higher employee expenses.
NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
Nirmal Bang Report
Following Zota Health Care Ltd.'s September-quarter results, Nirmal Bang has maintained its Buy rating on the stock, trimming its target price to Rs 1,670 from Rs1,679, implying a potential upside of 26% from the reports current price.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
The brokerage expects revenues to clock a compound annual growth rate of 62% over FY26–FY28E, driven by store additions, improved operations and continued network scale-up.
Nirmal Bang expects the company to continue to be EBITDA positive and continue to value the company at 20 times Sept FY30E EV/EBITDA.
Zota Healthcare Q2 FY27 Results Highlights
Zota Healthcare's Q2 FY27 showed sequential recovery at the operating level, but profitability remained weak.
Consolidated revenue grew 54.6% YoY to Rs 200 crore, led by Davaindia (up 76.2% YoY to Rs 170 crore) on higher footfall and a better wallet spend.
EBITDA turned positive Rs 3.1 crore on account of lower marketing expenses pertaining to brand ambassador spends but curtailed by higher employee expenses.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
